Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás de Prado; Lorena Rentero Redondo;

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice Alex Arenas; María José Moreta; Ingrid Ordás; Agnès Fernández-Clotet; Berta Caballol; Marta Gallego; Alejandro Vara; Rebeca Barastegui; Angel Giner; Cristina Prieto; Maria Carme Masamunt; Roberto Candia; Elena Ricart;

Infliximab en enfermedad inflamatoria intestinal. ¿Es necesario premedicar? Paulina Nuñez F.; Rodrigo Quera; Daniela Simian; Lilian Flores; Carolina Figueroa; Patricio Ibañez; Udo Kronberg; Jaime Lubascher; Gonzalo Pizarro;